QuidelOrtho (NASDAQ:QDEL) Shares Up 8.5% – Should You Buy?

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) traded up 8.5% during trading on Monday . The stock traded as high as $13.34 and last traded at $13.32. 1,401,162 shares changed hands during mid-day trading, a decline of 21% from the average daily volume of 1,774,812 shares. The stock had previously closed at $12.28.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on QDEL shares. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. UBS Group reiterated a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Monday, June 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, QuidelOrtho has a consensus rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Trading Up 1.7%

The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43. The firm has a 50 day moving average of $15.78 and a 200 day moving average of $17.20. The firm has a market cap of $959.29 million, a PE ratio of -0.91 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The business had revenue of $630.90 million during the quarter, compared to the consensus estimate of $618.72 million. During the same period last year, the business posted $0.12 earnings per share. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities analysts anticipate that QuidelOrtho Corporation will post 0.77 earnings per share for the current year.

Institutional Trading of QuidelOrtho

Several hedge funds and other institutional investors have recently modified their holdings of QDEL. Royal Bank of Canada boosted its holdings in QuidelOrtho by 1,218.7% in the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock worth $2,803,000 after buying an additional 74,112 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of QuidelOrtho by 10.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after acquiring an additional 21,968 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of QuidelOrtho by 210.9% in the first quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after acquiring an additional 13,876 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of QuidelOrtho in the second quarter valued at $1,313,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after purchasing an additional 2,309 shares during the period. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.